Osteopore To Take Singapore Orthopaedic Sales In-House From 2027
OSX: $0.004 +0.00% · MC: $2M
Osteopore’s subsidiary and DKSH Singapore have agreed to end their exclusive sales and marketing arrangement for Osteopore’s orthopaedic products at the end of 2026, ahead of its scheduled expiry, with Osteopore International set to take over from 2027. The company says direct management is intended to strengthen customer engagement as it expands 3D-printing services and prepares to introduce an injectable bone filler; DKSH’s arrangement began in 2024.

Comments